Introduction {#s1}
============

Intermediate filaments (IF) are a major component of the metazoan cytoskeleton, distinct from the actin and microtubule systems ([@bib74]; [@bib50]; [@bib12]; [@bib71]; [@bib72]). Humans express over 70 IF proteins, including both cytoplasmic (e.g., vimentin, keratins, neurofilaments) and nuclear (lamins) members, many with tissue-specific functions ([@bib111]). All IF proteins comprise a central, conserved α-helical rod domain, as well as amino-terminal head and carboxy-terminal tail domains of varying lengths ([@bib74]; [@bib50]; [@bib12]; [@bib71]; [@bib72]). IF proteins homo- or heterodimerize through the parallel association of their rod domains into coiled coils, forming an elongated dimer of \~45--48 nm for cytoplasmic IFs and \~50--52 nm for nuclear lamins ([@bib94]; [@bib1]). These dimers laterally associate in antiparallel fashion to form tetramers, which in turn assemble into \~65 nm unit-length filaments (ULFs) composed of eight tetramers ([@bib50]; [@bib12]; [@bib48]). Finally, ULFs associate end-to-end to assemble mature IFs, measuring \~10 nm across ([@bib74]; [@bib50]; [@bib12]).

Unlike actin- or microtubule-based structures, IFs are nonpolar and do not serve as tracks for molecular motors. Instead, IFs contribute to the mechanical integrity of the cell through their unique viscoelastic properties ([@bib74]; [@bib50]; [@bib12]; [@bib71]; [@bib72]). In general, the IF network is flexible under low strain but stiffens and resists breakage under an applied force ([@bib58]; [@bib31]; [@bib41]; [@bib67]). Remarkably, individual IFs can be stretched up to 3.6-fold before rupture, demonstrating their elastic nature, as compared to actin cables or microtubules ([@bib67]). The IF network is also highly dynamic in vivo, with IF subunits (likely tetramers) exchanging rapidly at many points along mature filaments ([@bib82]; [@bib36]; [@bib84]; [@bib116]; [@bib51]; [@bib80]; [@bib117]; [@bib89]). Similarly, the IF cytoskeleton quickly reorganizes in response to numerous physiological cues, including cell cycle progression, migration, spreading, and growth factor stimulation ([@bib74]; [@bib50]; [@bib12]; [@bib71]; [@bib72]; [@bib125]; [@bib46]).

IFs participate in many cellular processes, including maintenance of cell shape, organelle anchoring, cell motility, and signal transduction ([@bib47]; [@bib3]). For example, vimentin, among the most widely studied IF proteins, is required for mesenchymal cell adhesion, migration, chemotaxis, and wound healing in both cell culture and animal models ([@bib57]; [@bib122]; [@bib25]; [@bib99]; [@bib83]). Vimentin IFs also contribute to the mechanical properties of the cytoplasm, and stabilize and localize mitochondria ([@bib87]; [@bib8]; [@bib40]; [@bib24]). Importantly, genetic lesions that dysregulate the IF cytoskeleton cause a wide range of human diseases, including skin and nail disorders (keratins), cardiomyopathies (desmin), lipodystrophy, muscular dystrophy and progeria (lamins), giant axonal neuropathy and Charcot-Marie-Tooth disease (neurofilaments), and cataracts (vimentin) ([@bib91]; [@bib90]). In addition, the ectopic expression of wild type (WT) vimentin is a hallmark of the epithelial-to-mesenchymal transition, and is widely observed in human metastatic cancers ([@bib101]; [@bib88]; [@bib18]). IFs are likely functionally important in this context, because vimentin expression levels correlate with the invasive phenotypes of breast, prostate, and other epithelial cancers ([@bib101]; [@bib121]; [@bib130]; [@bib118]). Finally, the IF cytoskeleton is also intimately involved in host-microbe interactions ([@bib34]; [@bib79]). For example, changes in vimentin IFs are implicated in the adhesion, invasion, and replication of a wide range of bacteria, including such important pathogens as *Chlamydia trachomatis* ([@bib70]; [@bib59]; [@bib108]; [@bib2]), *Mycobacterium tuberculosis* ([@bib33]; [@bib78]), *Streptococcus pyogenes* (*[@bib7]; [@bib53]; [@bib73])* and *Salmonella enterica* ([@bib86]; [@bib39]).

Despite this broad pathophysiological significance, the regulation of IF cytoskeleton morphology, dynamics, and signaling functions remains incompletely understood. Several recent lines of evidence indicate that post-translational modifications (PTMs) are an important mode of IF regulation, and indeed all IFs are subject to extensive PTMs, including phosphorylation, ubiquitination, sumoylation, acetylation, farnesylation, and glycosylation ([@bib109]). However, in most cases, the functional impact of these PTMs on IF structure and function is poorly characterized.

To better understand the dynamic regulation of the IF cytoskeleton, we focused on O-linked β-*N*-acetylglucosamine (O-GlcNAc), an intracellular form of protein glycosylation that reversibly decorates serine and threonine residues on thousands of nuclear, cytoplasmic, and mitochondrial proteins. In mammals, O-GlcNAc is added by O-GlcNAc transferase (OGT) and removed by O-GlcNAcase (OGA) ([Figure 1A](#fig1){ref-type="fig"}) ([@bib42]; [@bib44]; [@bib45]). O-GlcNAc cycling controls many processes, including nutrient sensing, cell cycle progression, and apoptosis ([@bib42]; [@bib44]), and is essential, as genetic ablation of OGT or OGA is lethal in mice ([@bib102]; [@bib63]; [@bib123]). In addition, aberrant O-GlcNAc cycling is implicated in numerous human diseases, including cancer ([@bib44]; [@bib76]; [@bib124]; [@bib106]), diabetes ([@bib114]; [@bib43]; [@bib77]), cardiac dysfunction ([@bib26]; [@bib27]; [@bib17]; [@bib16]), and neurodegeneration ([@bib128]; [@bib115]; [@bib129]; [@bib131]).

![Vimentin engages in O-GlcNAc-mediated protein-protein interactions within assembled IFs.\
(**A**) O-GlcNAc transferase (OGT) uses the nucleotide-sugar donor UDP-GlcNAc to add O-GlcNAc to protein substrates. O-GlcNAcase (OGA) removes O-GlcNAc moieties. 5SGlcNAc and Thiamet-G are specific small molecule inhibitors of OGT and OGA, respectively. (**B**) 293T cells were treated with DMSO vehicle or GlcNDAz (48 hr) and UV light (or not) as indicated, and lysates were prepared in denaturing buffer and analyzed by IB. O-GlcNAc-mediated protein-protein interactions manifest as high molecular weight GlcNDAz-crosslinked complexes (labeled). Heavily glycosylated nucleoporin-62 is a positive control, whereas unglycosylated tubulin is a negative control. Vimentin IB was performed with the D21H3 antibody. (**C**) 293T cells were transfected with OGT-myc or OGA-myc constructs, as indicated, and subjected to GlcNDAz crosslinking as above. Crosslinked and uncrosslinked endogenous vimentin species were detected in lysates made in denaturing buffer by IB (D21H3 antibody). (**D**) 293T cells were subjected to GlcNDAz crosslinking as above. Then, soluble (disassembled) and insoluble (assembled) vimentin populations were separated by differential extraction, as described ([@bib49]). Low, low ionic strength buffer. High, high dil., high ionic strength buffer (loaded both as-is and diluted, as recommended ([@bib49])). 8M urea extracts fully assembled IFs. Crosslinked and uncrosslinked vimentin species were detected by IB (D21H3 antibody). (**E**) 293T cells were treated with GlcNDAz for 48 hr, treated with 1% IDPN or DMSO vehicle for 30 min, and exposed to UV. Then, cells were subjected to differential extraction, as above, and analyzed by IB (D21H3 antibody). Note that the uncrosslinked vimentin band appears in the 8M urea fraction of IDPN-treated cells because IDPN treatment collapses vimentin IFs into insoluble aggregates (see [Figure 1---figure supplement 2G](#fig1s2){ref-type="fig"}) ([@bib23]).\
10.7554/eLife.31807.007Figure 1---source data 1.Proteomic analysis of vimentin GlcNDAz crosslinks.Full proteomics results are available for download as a Scaffold (.sf3) file on the *eLife* web site. Free software to view Scaffold files is available at <http://www.proteomesoftware.com/products/scaffold/download/>.](elife-31807-fig1){#fig1}

Interestingly, numerous IF proteins are O-GlcNAcylated ([@bib65]; [@bib15]). For example, keratin-18 glycosylation is required for the recruitment and activation of the pro-survival kinase Akt, and mice expressing an unglycosylatable keratin-18 mutant are sensitized to chemical injury of the liver and pancreas ([@bib69]; [@bib68]). Several neurofilament proteins are also glycosylated, especially in axons, and neurofilament-M O-GlcNAcylation is reduced in both human Alzheimer's disease patients and a rat model of amyotrophic lateral sclerosis, suggesting a potential role for dysregulated IF glycosylation in neurodegeneration ([@bib22]; [@bib21]; [@bib75]; [@bib19]; [@bib13]). Finally, vimentin is O-GlcNAcylated on several sites, primarily in its head domain ([@bib107]; [@bib119]). Changes in vimentin glycosylation have been observed in models of differentiating adipocytes ([@bib56]) and neurons ([@bib30]), and a recent study observed a correlation between vimentin O-GlcNAcylation and the invasive potential of cholangiocarcinoma ([@bib93]), implicating glycosylation changes in both the physiological and pathological functions of vimentin. These studies suggest that O-GlcNAcylation is a prominent mode of IF regulation in homeostasis and disease alike. Nevertheless, the mechanistic and functional impacts of O-GlcNAcylation on IF proteins remain largely unexplored.

Here, we report that vimentin O-GlcNAcylation is required for the structure and function of IFs in human cells. We demonstrate that site-specific glycosylation of vimentin mediates its self-association, and is required in human cells for both IF morphology and its facilitating role in cell migration. In addition, we provide evidence that vimentin glycosylation is co-opted by an intracellular bacterial pathogen to produce a replicative niche, revealing a new connection between IF O-GlcNAcylation and microbial pathogenesis. Our results provide new insight into the physiological role of vimentin glycosylation in particular, and may have broad implications for our understanding of the dynamic regulation of the IF cytoskeleton in general.

Results {#s2}
=======

Vimentin is O-GlcNAcylated at multiple sites in its head domain ([@bib107]; [@bib119]), but the functional consequences of this modification are poorly understood. Like other intracellular PTMs, O-GlcNAc can exert a wide range of biochemical effects on its substrates, including conformational change, relocalization or destruction ([@bib42]; [@bib44]; [@bib102]; [@bib63]; [@bib85]; [@bib5]). Because IF proteins self-associate into homo-oligomeric complexes, we hypothesized that vimentin O-GlcNAcylation might influence its protein-protein interactions. Indeed, O-GlcNAc regulates protein-protein interactions in other contexts, including chromatin remodeling, nutrient sensing, and the interaction between keratins and Akt ([@bib69]; [@bib32]; [@bib113]; [@bib20]). However, physiological O-GlcNAc-mediated interactions are often low-affinity, sub-stoichiometric, and transient, presenting a technical barrier to studying them ([@bib42]; [@bib44]; [@bib102]; [@bib63]; [@bib85]; [@bib5]; [@bib113]).

To address these challenges, we used a chemical biology method to capture and characterize O-GlcNAc-mediated protein-protein interactions in living cells ([@bib126]). In this strategy, cells are metabolically labeled with a GlcNAc analog bearing a diazirine photocrosslinking moiety, termed 'GlcNDAz\' ([@bib126]). GlcNDAz is accepted by the GlcNAc salvage pathway, converted to the nucleotide-sugar UDP-GlcNDAz, and used by OGT to decorate its native substrates ([@bib126]). Brief treatment of GlcNDAz-labeled live cells with UV light triggers the covalent crosslinking of O-GlcNDAz moieties to any binding partner proteins within \~2--4 Å of the sugar ([@bib126]). Because of this short radius, GlcNDAz crosslinking occurs exclusively at sites where the glycan contributes to the interaction interface, without crosslinking to distant or nonspecific proteins ([@bib126]). Therefore, GlcNDAz is a powerful tool for identifying direct, glycosylation-mediated interactions between endogenous proteins in live cells ([@bib126]).

To determine whether vimentin engages in O-GlcNAc-mediated protein-protein interactions, we treated human cells with GlcNDAz and UV, and analyzed lysates by immunoblot (IB). Endogenous vimentin crosslinked into distinct, high molecular weight bands that were diazirine- and UV-dependent ([Figure 1B](#fig1){ref-type="fig"}), indicating that O-GlcNAc mediates protein-protein interactions between vimentin and one or more binding partners. Overexpression of OGT caused an increase in vimentin crosslinks ([Figure 1C](#fig1){ref-type="fig"}), whereas overexpression of OGA ([Figure 1C](#fig1){ref-type="fig"}) or treatment with a small molecule inhibitor of OGT, abbreviated 5SGlcNAc ([@bib35]) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), reduced crosslinking, confirming that this assay reports on authentic O-GlcNAc-mediated interactions, and not a nonspecific action of the GlcNDAz probe.

We next sought to identify the O-GlcNAc-mediated binding partner(s) of vimentin detected in our crosslinking assay. We created a myc-6xHis-tagged human vimentin construct and confirmed that it crosslinked via GlcNDAz similarly to endogenous vimentin ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Then, we purified preparative amounts of vimentin crosslinks from transfected cells via tandem immunoprecipitation (IP) and immobilized metal affinity chromatography, and analyzed the crosslinks by mass spectrometry (MS)-based proteomics ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2D,E](#fig1s2){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). We obtained 80% tryptic peptide coverage of vimentin in these samples, without significant enrichment of other proteins, beyond common contaminants ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). This result suggested that the vimentin GlcNDAz crosslinks represent homotypic, O-GlcNAc-mediated vimentin-vimentin interactions.

In vivo, vimentin exists in a range of assembly states, from soluble tetramers and ULFs, to relatively insoluble mature IFs ([@bib74]; [@bib50]; [@bib12]; [@bib71]; [@bib72]). To determine the assembly state of the crosslinked vimentin species, we performed a well-established differential extraction procedure ([@bib96]) on GlcNDAz-crosslinked cells. The GlcNDAz crosslinks of endogenous vimentin extracted into a denaturing buffer but not low or high ionic strength non-denaturing buffers, indicating that the crosslinks occur within the highly assembled filament population ([Figure 1D](#fig1){ref-type="fig"}) ([@bib96]). Importantly, extracted crosslinks remained soluble when exchanged from denaturing into non-denaturing buffers, demonstrating that GlcNDAz crosslinking per se does not reduce vimentin solubility ([Figure 1---figure supplement 2F](#fig1s2){ref-type="fig"}). To further confirm that crosslinks occur within assembled IFs, we treated cells with β,β'-iminodipropionitrile (IDPN), which blocks vimentin assembly beyond the ULF state ([@bib23]). Consistent with previous reports, IDPN treatment abrogated vimentin IFs and caused the accumulation of vimentin aggregates ([Figure 1---figure supplement 2G](#fig1s2){ref-type="fig"}) ([@bib23]). In the crosslinking assay, IDPN also suppressed the formation of GlcNDAz-dependent adducts, indicating that the crosslinks occur in assembly states beyond ULFs ([Figure 1E](#fig1){ref-type="fig"}). Using quantitative IBs, we detected \~10% of endogenous vimentin crosslinked into GlcNDAz-dependent adducts ([Figure 1---figure supplement 2H](#fig1s2){ref-type="fig"}), though this measurement likely significantly underestimates the fraction of vimentin that engages in O-GlcNAc-mediated interactions, since several steps in the GlcNDAz crosslinking protocol are less than 100% efficient ([@bib126]; [@bib98]). Based on these results, we concluded that O-GlcNAc-mediated vimentin-vimentin interactions are prevalent in cells, and occur primarily within assembled IFs, but not in soluble pools of lower-order assembly states.

The Hart lab previously mapped several glycosylation sites on vimentin's flexible head domain ([@bib107]; [@bib119]). We used these results to identify vimentin O-GlcNAc sites that contribute to its homotypic, glycosylation-mediated interactions. We mutated each reported O-GlcNAcylation site to alanine and screened these constructs in the GlcNDAz crosslinking assay ([Figure 2](#fig2){ref-type="fig"}). Mutation of several individual residues, including T33, S34, and S39, reduced vimentin crosslinking, while mutation of S49 abolished all detectable crosslinks. Because of the dramatic reduction of crosslinking in the S49A mutant, we measured the fraction of total vimentin glycosylation occurring at S49. We transfected cells with vector, WT or S49A vimentin and then labeled them with GalNAz, an azide-bearing unnatural monosaccharide that we have described previously as a metabolic reporter of O-GlcNAcylation ([@bib6]; [@bib92]; [@bib11]). S49A mutant vimentin exhibited \~80% the GalNAz signal of WT ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), suggesting that approximately one-fifth of vimentin glycosylation occurs on S49 under these conditions. Together, these results suggest that robust and site-specific O-GlcNAcylation in the vimentin head domain mediates homotypic protein-protein interactions within IFs.

![Specific glycosylation sites in the vimentin head domain are required for homotypic, O-GlcNAc-mediated interactions.\
293T cells were transfected with GFP only (control) or WT or mutant vimentin-myc-6xHis constructs as indicated for 24 hr, subjected to GlcNDAz crosslinking, and analyzed by IB. Tubulin is a loading control.](elife-31807-fig2){#fig2}

We next tested whether O-GlcNAc-mediated interactions influence vimentin IF structure or function in live human cells. We used CRISPR/Cas9 methods to delete endogenous vimentin from two different human cell lines, selected single cell-derived clones, and confirmed the absence of vimentin mRNA and protein ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). Then, we stably reconstituted individual vimentin^−/−^ clones with WT or unglycosylatable point-mutant versions of a well-characterized vimentin-mEmerald fusion protein ([@bib82]; [@bib125]; [@bib47]; [@bib52]) to permit live-cell visualization of IFs. We verified that vimentin-mEmerald was expressed at uniform levels comparable to endogenous vimentin ([Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}), and that the mEmerald signal precisely coincided with anti-vimentin immunofluorescence in cells expressing both endogenous vimentin and vimentin-mEmerald ([Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}). These results confirmed that the vimentin-mEmerald construct is a faithful proxy for the untagged protein in this system. In our panels of vimentin-mEmerald-reconstituted cells, we included Y117L, a point-mutation in the rod domain that blocks vimentin assembly beyond the ULF stage ([@bib81]), as a positive control for IF disruption. We used fluorescence-activated cell sorting, IB and fluorescence microscopy to ensure equal expression of the various WT and mutant vimentin-mEmerald transgenes across reconstituted vimentin^−/−^ cell lines ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplements 1D](#fig3s1){ref-type="fig"},[3A](#fig3s3){ref-type="fig"}).

![Head domain glycosylation sites are required for vimentin IF assembly and morphology in vivo.\
(**A**) A vimentin^−/−^ HeLa clone was stably transduced with empty vector (control) or expression constructs encoding WT or mutant vimentin-mEmerald and then imaged by laser scanning confocal fluorescence microscopy. (**B**) Vimentin-reconstituted HeLa cells were imaged as in (**A**) and cells were scored for filaments or puncta (≥400 cells per genotype). Differences in both filament and puncta measurements are significant across all genotype comparisons (\*\*\*p\<0.001, Student's t-test) except for S49A and S49E, which are indistinguishable from each other.](elife-31807-fig3){#fig3}

Cells reconstituted with WT vimentin-mEmerald exhibited canonical IF morphology, whereas the Y117L-expressing cells lacked assembled filaments and instead displayed punctate structures consistent with ULFs ([Figure 3A,B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3A,B](#fig3s3){ref-type="fig"}). These results indicate that our reconstituted cell systems recapitulate the previously reported characteristics of WT and Y117L vimentin ([@bib81]; [@bib47]; [@bib97]). We also observed dramatic alterations in vimentin IF organization in several unglycosylatable point-mutants. For example, the S34A mutant, which had an intermediate phenotype in our crosslinking assay ([Figure 2](#fig2){ref-type="fig"}), displayed a partial defect in IF formation, with both punctate and filamentous fluorescence detected ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). Interestingly, the S49A mutant, which lacked detectable O-GlcNAc-mediated interactions in the GlcNDAz assay ([Figure 2](#fig2){ref-type="fig"}), exhibited a significant reduction of assembled IFs in live cells, displaying a higher proportion of punctate vimentin fluorescence as compared to WT ([Figure 3A,B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3A,B](#fig3s3){ref-type="fig"}). Importantly, the S49A mutation had no impact on vimentin stability ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), further ruling out an effect of vimentin expression level in this system.

These results suggested that O-GlcNAc on specific residues of vimentin, particularly S49, may be required for its homotypic assembly into mature IFs in live cells. However, S/T→A mutations eliminate all O-linked PTMs at the mutated site, including both O-GlcNAcylation and phosphorylation. Therefore, phenotypes arising from S/T→A mutations may be due to loss of phosphorylation, glycosylation, or both. Vimentin S49 is a known glycosylation site ([@bib107]; [@bib119]) but not a reported phosphorylation site, suggesting that the phenotypes we observed in the S49A mutant ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) are due to the loss of O-GlcNAc, and not the loss of phosphorylation. To further test this hypothesis, we reconstituted vimentin^−/−^ cells with a phosphomimetic S49E mutant. Vimentin-S49E-expressing cells displayed a loss of filament morphology and a proportion of puncta indistinguishable from the S49A mutant ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). These results suggest that the abnormal vimentin IF structures observed with the S49A mutant in live cells are due to the loss of glycosylation, not loss of phosphorylation, at S49.

We next investigated whether vimentin O-GlcNAcylation is required for known functions of IFs. The IF cytoskeleton facilitates cell migration, and vimentin^−/−^ cells and tissues exhibit migration defects ([@bib57]; [@bib122]; [@bib25]; [@bib99]; [@bib83]). We used a well-characterized Transwell assay ([@bib60]) to measure cell migration by vimentin-reconstituted cell lines across a collagen matrix. Consistent with prior reports in other systems ([@bib57]; [@bib122]; [@bib25]; [@bib99]; [@bib83]), vimentin^−/−^ cells stably transduced with empty vector or the Y117L mutant construct were impaired in serum-stimulated migration, relative to cells expressing WT vimentin ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Interestingly, vimentin-S49A-expressing cells also exhibited migration defects compared to WT ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). This result suggested that O-GlcNAc on vimentin may be required for optimal cell migration. To further confirm this hypothesis, we assayed the serum-induced migration of vimentin-reconstituted cells upon treatment with 5SGlcNAc or Thiamet-G, a specific small molecule inhibitor of OGA ([@bib127]) ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). 5SGlcNAc or Thiamet-G treatment each significantly inhibited the serum-induced migration of cells expressing WT vimentin, but not cells lacking vimentin or expressing the S49A mutant ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Taken together, these results indicate that O-GlcNAcylation of vimentin, especially on S49, is required for optimal serum-stimulated cell migration.

![Vimentin O-GlcNAcylation is required for cell migration.\
Vimentin^−/−^ HeLa cells reconstituted with empty vector or WT, S49A or Y117L vimentin-mEmerald expression constructs were serum-starved for 72 hr, treated with either vehicle control (DMSO), 100 µM 5SGlcNAc or 50 µM Thiamet-G for 6 hr, and then assayed by Transwell migration using 10% fetal bovine serum as a chemoattractant (or no serum, 'Control'). Migrated cells were stained with crystal violet and four fields of view were imaged and counted for each of four biological replicates. The WT DMSO serum-stimulated sample was defined as maximum migration and used to normalize all data. Serum-stimulated migration is impaired in cells lacking vimentin or expressing mutant vimentin. 5SGlcNAc and Thiamet-G each inhibit migration in cells expressing WT vimentin, but have no effect on cells lacking vimentin or expressing mutant vimentin. n = 4, \*\*\*p\<0.001, \*\*p=0.006, n.s. not significant, ANOVA followed by Student's t-test. For simplicity, only selected statistical comparisons are indicated on the graph. Please see [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"} for comprehensive statistical comparisons.\
10.7554/eLife.31807.016Figure 4---source data 1.Full statistical analyses of cell migration data.(**A**) Migration data were first compared by analysis of variance (ANOVA) using JMP software. The results of the ANOVA, as well as the effect test, are displayed. (**B**) Pairwise t-tests for all combinations of data points were performed. Level and --Level indicate the sample and the sample it is being compared to, respectively. The calculated difference, standard error, and upper and lower confidence levels (CL) are shown, as well as the p value for each t-test. (**C**) Comprehensive comparison of all samples and conditions. Any two samples that do not share a letter in column two are statistically significantly different from each other.](elife-31807-fig4){#fig4}

Several intracellular pathogens co-opt the IF cytoskeleton to stabilize the large membrane-bound vacuoles in which they replicate, presumably by providing structural scaffolds ([@bib34]; [@bib79]). For example, we previously showed that the obligate intracellular pathogen *Chlamydia trachomatis* recruits a meshwork of vimentin IFs to its vacuolar 'inclusion' compartment, stabilizing its replicative niche and shielding bacterial components from the host's cytoplasmic innate immune surveillance machinery ([@bib70]; [@bib59]; [@bib108]; [@bib2]). The molecular mechanisms of *Chlamydia*-induced vimentin recruitment and reorganization are incompletely understood. To examine the potential role of vimentin O-GlcNAcylation in these processes, we treated HeLa cells reconstituted with WT vimentin-mEmerald with vehicle control, 5SGlcNAc or Thiamet-G, infected them with *Chlamydia*, and visualized pathogen-containing inclusions and vimentin IFs by fluorescence microscopy ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We found that 5SGlcNAc treatment inhibited the formation of a vimentin meshwork around the inclusion, consistent with a requirement for vimentin glycosylation in IF remodeling during *Chlamydia* infection ([Figure 5A](#fig5){ref-type="fig"}). 5SGlcNAc treatment reduced the average size of the inclusions in infected cells and increased the number of extra-inclusion bacteria ([Figure 5B](#fig5){ref-type="fig"}), demonstrating that OGT activity is required for inclusion expansion and integrity. Thiamet-G treatment had little effect in these assays, likely because basal levels of O-GlcNAcylation are already sufficient for optimal *Chlamydia* replication ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

![*Chlamydia trachomatis* requires OGT activity and vimentin glycosylation sites to maintain inclusion integrity during infection.\
(**A**) HeLa cells reconstituted with WT vimentin-mEmerald were infected with *Chlamydia* for ten hours and treated with DMSO vehicle or 50 µM 5SGlcNAc for an additional 20 hr. Cells were fixed and immunostained for MOMP (to mark individual bacteria) and cap1 (to mark the inclusion membrane), along with vimentin-mEmerald imaging. Representative images are shown. Arrows indicate extra-inclusion bacteria. (**B**) Quantification of inclusion area and number of extra-inclusion bacteria from images in (**A**). n = 60, \*\*\*p\<0.001, Welch's t-test. (**C**) Reconstituted HeLa cell lines were infected with *Chlamydia* for 30 hr and then fixed, stained, and imaged as in (**A**). Representative images are shown. (**D**) Quantification of inclusion area from images in (**C**). n ≥ 54, \*\*\*p\<0.001, Welch's t-test. n.s., not significant. (**E**) HeLa cells reconstituted with empty vector were infected with *Chlamydia*, treated with DMSO vehicle or 50 µM 5SGlcNAc, and fixed and stained as in (**A**). Inclusion size (top; n = 20, p=0.21, Student's t-test) and extra-inclusional bacteria (bottom; n = 28, p=0.42, Student's t-test) were quantified. n.s., not significant.](elife-31807-fig5){#fig5}

We next tested whether O-GlcNAcylation of vimentin itself is required for inclusion integrity. We infected vimentin-reconstituted HeLa cell lines with *Chlamydia* and visualized vimentin IFs and bacteria by fluorescence microscopy. Compared to WT vimentin-expressing cells, cells expressing either the S49A or Y117L mutant vimentin displayed reduced IF recruitment to the inclusions, smaller average inclusion size, and larger numbers of bacteria escaping into the cytoplasm ([Figure 5C,D](#fig5){ref-type="fig"}). These data suggest that the site-specific glycosylation of vimentin itself is required for IF remodeling during *Chlamydia* infection. To further test this hypothesis, we infected empty vector-reconstituted vimentin^−/−^ cells with *Chlamydia* in the presence or absence of 5SGlcNAc. In contrast to our observations with cells expressing WT vimentin ([Figure 5A,B](#fig5){ref-type="fig"}), 5SGlcNAc had no impact on *Chlamydia* inclusion size or extra-inclusion bacteria in cells lacking vimentin, indicating that vimentin, but not other host- or pathogen-encoded targets, is required for the effects of 5SGlcNAc in this context ([Figure 5E](#fig5){ref-type="fig"}). We concluded that both OGT activity and vimentin glycosylation sites are required for IF reorganization during *Chlamydia* infection, and are co-opted by this pathogen to promote inclusion integrity and growth.

Discussion {#s3}
==========

The IF cytoskeleton plays critical roles in both physiological and pathological processes, but how cells regulate IF structure and function remains poorly understood. We provide evidence that site-specific glycosylation of the vimentin head domain regulates its homotypic association in human cells, and is required for both IF morphology and cell migration ([Figure 6](#fig6){ref-type="fig"}). In addition, site-specific O-GlcNAcylation of vimentin is exploited by an intracellular pathogen to promote its own replication, underlining the importance of IF dynamics in disease states. Because many IF proteins are O-GlcNAc-modified ([@bib65]; [@bib15]; [@bib69]; [@bib22]; [@bib21]; [@bib75]; [@bib19]; [@bib13]; [@bib107]; [@bib119]; [@bib110]; [@bib61]; [@bib112]), our results may provide new insight into the regulation of both vimentin in particular and the IF cytoskeleton in general.

![Site-specific glycosylation regulates the form and function of vimentin IFs.\
Our data suggest a model wherein glycosylation of the N-terminal vimentin head domain (red), particularly on S49, promotes homotypic vimentin-vimentin interactions, and assembly and/or maintenance of mature IFs under both homeostatic and *Chlamydia* infection conditions.](elife-31807-fig6){#fig6}

Early evidence for vimentin glycosylation was reported nearly twenty-five years ago ([@bib103]) and confirmed with sophisticated MS methods thirteen years later ([@bib107]; [@bib119]). However, the biochemical and cellular effects of this modification have remained largely uncharacterized. Through GlcNDAz crosslinking ([Figure 2](#fig2){ref-type="fig"}) and live-cell imaging ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), we determined that the vimentin glycosylation sites S34, S39 and especially S49 are required for normal homotypic vimentin-vimentin interactions and for IF morphology in live human cells. These O-GlcNAc-mediated interactions likely occur within assembled IFs and not smaller oligomeric states ([Figure 1D,E](#fig1){ref-type="fig"}). It is well established that portions of the vimentin head domain are required for filament assembly ([@bib29]), and that head domain PTMs (especially phosphorylation) govern IF dynamics in vivo ([@bib47]; [@bib29]; [@bib14]; [@bib28]; [@bib105]; [@bib37]; [@bib10]). Our results are consistent with this general model of regulated filament assembly/disassembly through head domain PTMs ([Figure 6](#fig6){ref-type="fig"}). Interestingly, however, internal deletion mutations within the head domain demonstrate that S49 itself is not required for vimentin filament formation in vitro or in vivo ([@bib104]). Therefore, we propose that the phenotypes observed in the S49A vimentin mutant are caused by a loss of PTM regulation, rather than simply a requirement for serine at that site.

Given the very short crosslinking radius of the GlcNDAz reagent (\~2--4 Å) ([@bib126]) and our MS proteomics analysis of the crosslinked complexes ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 2D,E](#fig1s2){ref-type="fig"}), the O-GlcNAc-mediated interactions we observe are likely homotypic dimeric or trimeric vimentin adducts. The precise molecular nature of these crosslinks, and why we observe multiple discrete crosslinked complexes, remain uncertain. The high MS proteomic coverage we obtained of vimentin and the lack of other proteins in the crosslinks ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}) suggest that the complexes do not contain other binding partner proteins or known protein-based PTMs of vimentin, such as SUMO ([@bib62]; [@bib120]). Because vimentin is multiply phosphorylated ([@bib47]; [@bib29]; [@bib14]; [@bib28]; [@bib105]; [@bib37]; [@bib10]), the crosslinks of distinct molecular weight ([Figures 1B](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}) could in principle represent different phospho-forms of vimentin. However, several commercially available anti-phospho-vimentin antibodies failed to recognize the crosslinked complexes by IB (not shown), and phosphatase treatment of crosslinked adducts had no effect on their SDS-PAGE migration ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), arguing against differential phosphorylation as an explanation.

Instead, we postulate that the discrete bands in the GlcNDAz-induced vimentin complexes represent different crosslinking geometries of vimentin multimers. Because the O-GlcNAc-mediated interactions we detect occur primarily in assembled IFs ([Figure 1D,E](#fig1){ref-type="fig"}), an individual glycan on the vimentin head domain (e.g., at residue S49) may contact the head domain of its dimeric partner, and/or the rod domain of a vimentin molecule in an adjacent dimer, and/or another vimentin molecule within the same ULF. These different crosslinking geometries might produce migration differences in our GlcNDAz/SDS-PAGE assay ([Figure 1B](#fig1){ref-type="fig"}).

Irrespective of the molecular identities of the individual adducts, the fact that we observe a highly reproducible crosslinking pattern suggests that O-GlcNAc mediates specific contacts among vimentin molecules, and not a large variety of nonspecific interactions, which would produce variable or smeared crosslinking ([@bib126]). This evidence of specific contacts is perhaps surprising, given the widely accepted model that the head domain of vimentin is intrinsically disordered ([@bib38]). It is possible that, in vivo, O-GlcNAcylation mediates site-specific contacts between glycans on one vimentin molecule and discrete glycan recognition sites or domains on adjacent vimentin molecules within assembled filaments. Interestingly, several prior reports identified a GlcNAc-binding property of vimentin on the cell surface ([@bib54]; [@bib55]; [@bib64]; [@bib66]). Although the physiological relevance of extracellular vimentin is controversial, these biochemical observations are reminiscent of our own, in that vimentin is reported to bind to GlcNAc residues in both cases. However, two mutations in vimentin that abolish extracellular GlcNAc binding, E382A and E396A ([@bib66]), do not reduce intracellular GlcNDAz crosslinking ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Therefore, our observations are distinct from the reported glycan-binding property of cell surface vimentin ([@bib54]; [@bib55]; [@bib64]; [@bib66]). The vimentin site(s) that bind O-GlcNAc moieties are not readily discernible from our MS studies, due to the unpredictable masses and fragmentation spectra of crosslinked adducts. However, the identification of these sites will be an important priority for future studies, because this information may elucidate the biophysical regulation of IF assembly and dynamics by O-GlcNAc.

At the cellular level, specific glycosylation sites of vimentin, including S34, S39 and especially S49, are essential for IF morphology and for facilitating serum-stimulated migration ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). We propose that O-GlcNAcylation at one or more of these sites influences the assembly and/or disassembly of vimentin filaments, as has been described for other PTMs. Indeed, phosphorylation of several residues in the vimentin head domain promotes IF disassembly in response to multiple stimuli ([@bib47]; [@bib29]; [@bib14]; [@bib28]; [@bib105]; [@bib37]; [@bib10]). O-GlcNAcylation and phosphorylation often compete for nearby or identical residues on specific protein substrates, giving rise to a complex functional interplay between these PTMs ([@bib44]; [@bib9]). Moreover, specific O-GlcNAc sites required for in vivo IF assembly in our work, such as S34 and S39 ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), can also be phosphorylated ([@bib47]; [@bib29]; [@bib14]; [@bib28]; [@bib105]; [@bib37]; [@bib10]). Therefore, reciprocal PTMs at certain sites may have antagonistic effects, with glycosylation of S34 or S39 promoting IF assembly, while phosphorylation at those sites induces disassembly.

In contrast, vimentin S49 is required for normal IF assembly in human cells ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) and is a known glycosylation site ([@bib107]; [@bib119]) but is not a reported phosphorylation site. These observations suggest a functional role for O-GlcNAc, but not O-phosphate, at this residue. In support of this hypothesis, a phosphomimetic S49E mutant phenocopies an S49A mutant in IF morphology ([Figure 3](#fig3){ref-type="fig"}), and an OGT inhibitor impacts on cell migration and *Chlamydia* inclusion size only in the presence of WT vimentin, but not in cells expressing S49A mutant vimentin or lacking vimentin ([Figures 4](#fig4){ref-type="fig"} and [5E](#fig5){ref-type="fig"}). Taken together, these results strongly indicate that (de)glycosylation of S49 is required for WT levels of cell migration and pathogen-induced IF remodeling. Although we cannot strictly rule out the possibility that S49 is phosphorylated under as-yet untested conditions, we suggest that S49 O-GlcNAcylation is required for homotypic vimentin-vimentin interactions ([Figure 2](#fig2){ref-type="fig"}), filament assembly ([Figure 3](#fig3){ref-type="fig"}), and downstream behaviors of the vimentin IF cytoskeleton in normal and pathological contexts ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}).

Finally, our results indicate that O-GlcNAc-mediated vimentin IF assembly is required for *Chlamydia* inclusion expansion and integrity, because we observed smaller inclusions and more cytoplasmic bacteria in *Chlamydia*-infected cells expressing Y117L or S49A mutants of vimentin ([Figure 5C,D](#fig5){ref-type="fig"}). *Chlamydia* remodels the IF cytoskeleton to stabilize the inclusion during its replication phase, and deploys the CPAF protease to dismantle the IF cytoskeleton and promote bacterial release at late stages of infection ([@bib70]; [@bib59]; [@bib108]; [@bib2]). Our current data extend these results by demonstrating that vimentin filament remodeling by *Chlamydia* depends on both OGT activity ([Figure 5A,B](#fig5){ref-type="fig"}) and on the site-specific glycosylation of vimentin itself ([Figure 5C--E](#fig5){ref-type="fig"}). We detected WT levels of CPAF-mediated vimentin cleavage with the S49A and Y117L mutants ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), indicating that the phenotypes we observe are not due to differential vimentin cleavage during infection. The molecular mechanisms by which *Chlamydia* co-opts OGT activity and vimentin glycosylation sites (e.g., S49) to reshape the IF cytoskeleton remain to be determined, and will be an interesting focus of future studies.

In conclusion, we have shown that site-specific glycosylation of vimentin mediates its homotypic protein-protein interactions, and is required in human cells for IF morphology and cell migration. In addition, *Chlamydia* relies on OGT activity and particular vimentin glycosylation sites to remodel the IF cytoskeleton and promote inclusion expansion and integrity. Our results provide new insight into the biochemical and cell biological functions of vimentin O-GlcNAcylation. In addition, our work may have broad implications for other IF proteins. Numerous IF proteins are dynamically glycosylated *in vivo* ([@bib65]; [@bib15]; [@bib69]; [@bib22]; [@bib21]; [@bib75]; [@bib19]; [@bib13]; [@bib107]; [@bib119]; [@bib110]; [@bib61]; [@bib112]), and the S49 residue of vimentin is conserved both among vertebrate vimentin orthologs and in human desmin, another type III IF protein ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Therefore, site-specific O-GlcNAcylation may be a general mode of regulating IF dynamics and function. In the future, pharmacological modulation of O-GlcNAcylation may provide a way to manipulate filament form and function for therapeutic benefit in diseases of dysregulated IFs, ranging from neurodegeneration and cardiomyopathy to cancer.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\     Designation                     Source or reference                 Identifiers                         Additional information
  or resource                                                                                                                         
  --------------------------- ------------------------------- ----------------------------------- ----------------------------------- ------------------------
  Cell line (HeLa)            vimentin -/-                    this paper                                                              

  Cell line (293T/17)         293T vimentin -/-               this paper                                                              

  Cell line (HeLa)            HeLa                                                                                                    

  Cell line (293T/17)         293T/UAP1                       PMCID: PMC3323966                                                       Stably expressing\
                                                                                                                                      AGX1(F383G)

  Antibody                    Anti-O-GlcNAc RL2               Santa Cruz Biotechnology            Santa Cruz: sc-59624                1:300

  Antibody                    anti-myc 9E10                   Santa Cruz Biotechnology            Santa Cruz: sc-40                   1:300

  Antibody                    anti-tubulin                    Sigma-Aldrich                       Sigma: T6074                        1:10,000

  Antibody                    anti-nucleoporin-62             BD Biosciences                      BD Biosciences: 610498              1:1,000

  Antibody                    anti-vimentin D21H3             Cell Signaling                      Cell Signaling: 5741                1:1,000; 1:100

  Antibody                    anti-vimentin V9                Sigma-Aldrich                       Sigma-Aldrich: V6389                1:1,000

  Antibody                    anti-GFP                        Thermo Fisher Scientific            ThermoFisher: A11122                

  Antibody                    Goat anti-rabbit IgG            Southern Biotechnology              Southern Biotech: 4030-05           1:5,000

  Antibody                    goat anti-mouse IgG             Southern Biotechnology              Southern Biotech: 1030-05           1:5,000

  Antibody                    goat anti-mouse k light chain   Southern Biotechnology              Southern Biotech: 1050-05           1:5,000

  Antibody                    Goat anti-rabbit IgG (H+L)\     Thermo Fisher Scientific            Thermo Fisher Scientific: A-11012   1:5,000
                              Alexa Fluor 594 conjugate                                                                               

  Antibody                    goat anti-mouse IgG (H+L)\      Thermo Fisher Scientific            Thermo Fisher Scientific: A-11005   1:5,000
                              Alexa Fluor 594 conjugate                                                                               

  Antibody                    goat anti-rabbit IgG (H+L)\     Li-Cor                              Li-Cor: 925-32211                   1:5,000
                              IRDye 800CW conjugate                                                                                   

  Antibody                    goat anti-mouse IgG (H+L)\      Li-Cor                              Li-Cor: 925-32210                   1:5,000
                              IRDye 800CW conjugate                                                                                   

  Recombinant DNA reagent     mEmerald-vimentin-N-18          Addgene                             Addgene: 54301                      

  Recombinant DNA reagent     pLenti CMV/TO Hygro DEST                                            Addgene plasmid: 17291              

  Recombinant DNA reagent     pLenti CMV Neo DEST (705-1)                                         Addgene plasmid: 17392              

  Recombinant DNA reagent     mEmerald-vimentin-N-18/\        this paper                                                              
                              pLenti6 CMV Neo                                                                                         

  Recombinant DNA reagent     mEmerald-vimentin-N-18/\        this paper                                                              
                              pLenti6 CMV Hygro                                                                                       

  Chemical compound, drug     Thiamet-G                       Duke Small Molecule\                                                    
                                                              Synthesis Facility                                                      

  Chemical compound, drug     Ac45SGlcNAc                     Benjamin Swarts, Central\                                               
                                                              Michigan University                                                     

  Chemical compound, drug     Advansta ECL                    Advansta                                                                

  Sequence-based reagent      vimentin sgRNA                  Duke Functional Genomics Facility                                       

  Sequence-based reagent      vimentin sgRNA                  Duke Functional Genomics Facility                                       

  Sequence-based reagent      vimentin sgRNA                  Duke Functional Genomics Facility                                       

  Biological sample (virus)   Cas9 Lentivirus                 Duke Functional Genomics Facility                                       

  Commercial assay or kit     pENTR Directional\              Thermo Fisher Scientific            Thermo Fisher Scientific: K240020   
                              TOPO cloning kit                                                                                        

  Commercial assay or kit     Gateway LR Clonase II Enzyme    Thermo Fisher Scientific            Thermo Fisher Scientific:11791100   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Chemicals and enzymes {#s4-1}
---------------------

Thiamet-G was synthesized as described ([@bib127]) by the Duke Small Molecule Synthesis Facility (DSMSF). Ac~4~5SGlcNAc was synthesized as described ([@bib35]) and was a gift of Benjamin Swarts, Central Michigan University. Ac~3~GlcNDAz-1P(Ac-SATE)~2~ was synthesized in-house or by the DSMSF as described ([@bib126]). All other chemicals were purchased from Sigma unless otherwise noted. Lambda phosphatase was purchased from New England Biolabs.

Mammalian cells and cell culture {#s4-2}
--------------------------------

Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 µg/ml streptomycin and kept at 37°C with 5% CO~2~. Cell lines were obtained from ATCC or the Duke Cell Culture Facility. In all cases, authenticity was verified using morphology, karyotyping, and PCR-based approaches (e.g., short tandem repeat profiling) and tested negative for *Mycoplasma* (PCR test) by the vendor at the time of purchase. HeLa and 293T cells were selected because they are well-established model systems for the human IF cytoskeleton and *Chlamydia* infection.

GlcNDAz crosslinking {#s4-3}
--------------------

O-GlcNAc-mediated protein crosslinking was performed essentially as described ([@bib126]). Briefly, Ac~3~GlcNDAz-1P(Ac-SATE)~2~ (GlcNDAz precursor) was added to a final concentration of 100 µM to the culture medium of 293T cells stably expressing AGX1(F383G) ([@bib126]). DMSO served as the vehicle control treatment. Dishes were incubated in the dark for 24 hr, dosed again with GlcNDAz precursor, and incubated for an additional 24 hr.

To crosslink and harvest, dishes were placed on ice and washed carefully twice with 10 ml of cold phosphate-buffered saline (PBS) twice. With dishes still on ice, 4 ml of cold PBS were added, lids were removed, and plates were exposed to 365 nm UV light for 20 min. Then, cells were resuspended in PBS by scraping and/or pipetting, pelleted by centrifugation, and lysed in either 8 M urea for IB, or IP buffer (150 mM NaCl, 20 mM Tris pH 7.4, 1% Triton X-100, 0.1% SDS) for IPs.

Immunoblotting (IB) {#s4-4}
-------------------

The concentrations of protein samples were obtained via bicinchoninic acid (BCA) assay according to the manufacturer's instructions (Thermo) and protein concentration was normalized across all samples within each experiment. One-third the volume of 4X SDS-PAGE loading buffer was added and the sample was heated to 95°C for 3 min (except in the case of samples prepared in 8 M urea). Samples were then loaded onto a polyacrylamide gel and run at 165 V.

Unless otherwise noted, IBs detection was performed by enhanced chemiluminescence (ECL). For ECL IBs, SDS-PAGE gels were transferred onto PVDF membrane using a BioRad semi-dry transfer system with transfer buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8, 20% methanol) using standard methods. After transfer, membranes were blocked in 5% bovine serum albumin (BSA) in Tris-buffered saline with Tween (TBST; Tris-buffered saline, 0.1% Tween-20) overnight at 4°C with gentle rocking. Primary antibody dilutions were prepared in TBST+BSA and incubated overnight with gentle shaking at 4°C. The next day, membranes were washed three times with TBST and incubated with the appropriate secondary antibody for 1.5 hr at room temperature. Membranes were again washed three times with TBST, developed with Advansta ECL reagent, and exposed to film. The following primary antibodies were used: Anti-O-GlcNAc RL2 (Santa Cruz sc-59624), anti-myc 9E10 (Santa Cruz sc-40), anti-tubulin (Sigma T6074), anti-nucleoporin-62 (BD Biosciences 610498), anti-vimentin (clone D21H3, Cell Signaling 5741), anti-vimentin (clone V9, Sigma-Aldrich V6389), anti-phospho-(Ser/Thr) Akt substrate (Cell Signaling 59624), anti-GFP (ThermoFisher; A11122), MOMP (a gift from Ken Fields, University of Kentucky). The following horseradish peroxidase-conjugated secondary antibodies were used: Goat anti-rabbit IgG (Southern Biotech 4030--05), goat anti-mouse IgG (Southern Biotech 1030--05), goat anti-mouse κ light chain (Southern Biotech 1050--05).

For quantitative fluorescent IBs, samples were separated by SDS-PAGE, electroblotted onto nitrocellulose membranes, blocked and probed as described above. The following secondary antibodies were used: Goat anti-rabbit IgG (H + L) Alexa Fluor 594 conjugate (Thermo Fisher Scientific A-11012), goat anti-mouse IgG (H + L) Alexa Fluor 594 conjugate (Thermo Fisher Scientific A-11005), goat anti-rabbit IgG (H + L) IRDye 800CW conjugate (Li-Cor, 925--32211), goat anti-mouse IgG (H + L) IRDye 800CW conjugate (Li-Cor, 925--32210). Blots were washed in TBST and scanned and analyzed on a Li-Cor Odyssey imaging system.

Plasmid construction {#s4-5}
--------------------

The sequence of human vimentin isoform 1 was amplified using PCR and the following primers: Forward: 5' cgcggatccgccaccatgtccaccaggtccgtg 3'; Reverse: 5' cgtctagattcaaggtcatcgtgatgctga 3'. The resulting PCR product and pcDNA3.1(+)/myc-His A vector (Invitrogen) were digested with BamHI and XbaI (New England Biolabs) and the vector treated with calf intestinal alkaline phosphatase (New England Biolabs) according to the manufacturer's instructions. PCR product and vector were mixed in a 3:1 molar ratio and incubated with T4 DNA ligase (New England Biolabs) in the provided buffer for 1 hr. This reaction was transformed into *E. coli* strain DH5α and the resulting colonies were cultured, miniprepped and sequenced using standard methods. The OGT-myc/6xHis and OGA-myc constructs have been described previously ([@bib6]).

The sequence of mEmerald-vimentin-N-18 (Addgene plasmid \#54301) was amplified using primers complementary to vimentin and GFP (Forward: 5' caccgccaccatgtccaccaggtccgtg 3'; Reverse: 5' cgcaacgaattctcaatgtccaccaggtccgt). The resulting PCR product was cloned into a pENTR vector using the pENTR Directional TOPO cloning kit (Fisher Scientific \#K240020) according to the manufacturer's instructions. This vector was used in a Gateway LR Clonase II Enzyme reaction, according to manufacturer's instructions (Invitrogen), with pLenti CMV Neo DEST (705-1) (Addgene plasmid \#17392), or pLenti CMV/TO Hygro DEST (Addgene plasmid \# 17291). Vimentin mutants were created from WT expression constructs via standard site-directed mutagenesis protocols using Agilent online primer design tools, oligonucleotides synthesized by IDT, and Phusion polymerase according to the manufacturer's instructions (Thermo Fisher). Mutagenesis was performed on vimentin-mEmerald in the pENTR vector prior to transfer to the appropriate destination vector. The integrity of all constructs was confirmed by Sanger sequencing through the entire open reading frame of each construct (Eton Bioscience).

Transfections {#s4-6}
-------------

30 µl of Trans-IT-293 transfection reagent (Mirus) was added to 750 µl of Opti-MEM medium (Life Technologies), vortexed and centrifuged briefly, and incubated at room temperature for 15 min. Then, 10 µg DNA was added to the mixture and vortexing and centrifuging were repeated, followed by an additional 15 min at room temperature. The entire reaction was added drop-wise to adherent cells.

Immunoprecipitation (IP) {#s4-7}
------------------------

Samples were extracted in IP buffer (150 mM NaCl, 20 mM Tris pH 7.4, 1% Triton X-100, 0.1% SDS), diluted to 1 mg/ml total protein concentration, and 3 µg of antibody was added for each 1 mg of protein used. IPs were incubated at 4°C overnight with gentle agitation. The next day, washed protein-A/G agarose beads (Thermo) were added to the tubes and rotated at room temperature for 1.5 hr. The beads were then isolated by centrifuging at 600 g for 1 min and the supernatants were discarded. Beads were washed four times with 1 ml of IP buffer and eluted with three times the bead volume of elution buffer (8M urea, 150 mM NaCl; if the samples were to be further purified by nickel, this buffer also contained 10 mM imidazole).

Differential extraction {#s4-8}
-----------------------

Differential extraction was performed essentially as described ([@bib96]). Briefly, 293 T cells were grown to confluency, treated with GlcNDAz precursor and UV-crosslinked as above, and washed three times on the plate with PBS containing 2 mM MgCl~2~ at room temperature. After removing PBS, attached cells were incubated in 1 ml of low-detergent buffer (10 mM MOPS pH 7, 10 mM MgCl~2~, 1 mM EGTA, 0.15% Triton X-100, plus 7.5 µl saturated phenylmethane sulfonyl fluoride (PMSF) solution in ethanol, added fresh, in 1x PBS) for five minutes at room temperature with gentle agitation. The buffer was removed and cleared by benchtop centrifugation, and the resulting supernatant was reserved as the soluble cell fraction. Plates were then incubated on ice in 1 ml of ice-cold high-detergent buffer (10 mM MOPS pH 7, 10 mM MgCl2, 1% Triton X-100, plus 7.5 µl saturated PMSF solution and 50 mg Benzonase, added fresh, in 1x PBS) for 3 min. Then, 250 µl of ice-cold 5 M NaCl was added, cells were resuspended by pipetting, and samples were cleared by centrifugation. The resulting supernatant was saved as the cytoskeletal fraction, including intermediate vimentin assembly states ([@bib96]). Finally, the pellet was resuspended by pipetting in 250 µl of 8 M urea in PBS to solubilize the remaining material (e.g., assembled IFs) ([@bib96]).

Buffer exchange {#s4-9}
---------------

Zeba spin desalting columns (Thermo Fisher, 89890) were washed with 1 ml of IP buffer and centrifuged at 1000 g for 2 min three times, according to the manufacturer's instructions. Samples were applied to the center of the column and 40 µl of IP buffer was applied after sample absorption into the resin. The column was centrifuged for 2 min at 1000 g and sample was collected in 1.5 ml centrifuge tubes.

Mass spectrometry-based proteomics {#s4-10}
----------------------------------

293T cells stably expressing AGX1(F383G) ([@bib126]) were transfected with a vimentin-myc-6xHis construct, treated with GlcNDAz precursor, and UV-crosslinked as above. Crosslinked and uncrosslinked vimentin-myc-6xHis was isolated first through anti-myc IP, as above. Samples were eluted from the protein A/G beads in 8 M urea, 150 mM NaCl and 10 mM imidazole in PBS and incubated with nickel-NTA resin (Qiagen) rotating at room temperature for 2 hr. The resin was washed three times with the same buffer and eluted with 8 M urea, 150 mM NaCl and 250 mM imidazole in PBS for 15 min. Eluents were separated by SDS-PAGE and stained with InstantBlue gel stain (Thermo Fisher). Bands corresponding to crosslinks were excised by hand, and analyzed by in-gel digest and MS/MS proteomics by the Duke Proteomics and Metabolomics Shared Resource. For more details, please see <https://genome.duke.edu/cores-and-services/proteomics-and-metabolomics/protein-characterization>

GalNAz labeling and click reactions {#s4-11}
-----------------------------------

GalNAz labeling was performed essentially as described ([@bib6]; [@bib92]; [@bib11]). Briefly, 293T cells were incubated with DMSO vehicle or 100 µM Ac~4~GalNAz for 24 hr. To harvest, cells were washed twice with PBS and resuspended in click lysis buffer (1% Triton X-100, 1% SDS, 150 mM NaCl, 20 mM Tris pH 7.4, 5 µM PUGNAc, protease inhibitor cocktail). After sonication and centrifugation, protein concentration was measured via BCA assay.

2.5 mg of protein were used in 875 µl total reaction volume for each click reaction. To these reactions were added 5 mM sodium ascorbate, 25 µM alkyne-Cy5 probe ([@bib92]), 100 µM TBTA, and 1 mM CuSO~4~. Samples were incubated in the dark at room temperature for 1 hr with gentle agitation and quenched with 10 mM EDTA. Samples were then diluted with 1% Triton X-100, 150 mM NaCl, 20 mM Tris pH 7.4, 1 mM EDTA, 5 µM PUGNAc and protease inhibitors to bring SDS concentration to 0.1%. 6.75 µg anti-myc (9E10) antibody were added to each sample and IPs were incubated at 4°C overnight with gentle agitation. The next day, washed protein-A/G agarose beads (Thermo) were added to the tubes and rotated at room temperature for 1 hr. The beads were then isolated by centrifuging at 600 g for 1 min and the supernatants were discarded. Beads were washed four times with 1 ml of IP buffer, eluted with three times the bead volume of SDS-PAGE loading buffer, and boiled for 5 min at 95°C. Samples were analyzed by SDS-PAGE and fluorescence scanning on a Li-Cor Odyssey imaging system.

Generation and validation of vimentin^−/−^ cells by CRISPR/Cas9 deletion {#s4-12}
------------------------------------------------------------------------

Three single guide RNA (sgRNA) sequences targeting the human vimentin locus were designed and validated via the Surveyor assay ([@bib95]) by the Duke Functional Genomics facility: Vim-1: 5' GGACGAGGACACGGACCTGG 3'; Vim-2: 5' CATCCTGCGGTAGGAGGACG 3'; Vim-3: 5' GGACACGGACCTGGTGGACA 3'. An sgRNA targeting the AAVS1 'safe harbor' locus ([@bib100]) was used as a control.

HeLa or 293T cells were added to a 6-well plate at \~40--60% confluency and allowed to attach for 24 hr. Then, cells were infected by adding 50 µl of a Cas9 lentivirus (Addgene plasmid \#52961), produced by the Duke Functional Genomics Facility, in DMEM plus 8 µg/ml polybrene drop-wise to each well. Plates were centrifuged at 700 g for 30 min and incubated under standard conditions for 24 hr. Then, the medium was changed to DMEM without polybrene and the cells were allowed to recover for 3 days. Cells were selected and maintained with blasticidin (5 µg/ml for 293T, 3 µg/ml for HeLa) for several passages before infection with sgRNA viruses.

HeLa or 293T cells stably transduced with lentiviral Cas9 were added to a 6-well plate at \~40--60% confluency and allowed to attach for 24 hr. Then, cells were infected with sgRNA-expressing lentivirus produced by the Duke Functional Genomics Facility in DMEM plus 8 µg/ml polybrene, and 50 µl of virus was added drop-wise to each well. Plates were centrifuged at 700 g for 30 min and incubated under standard conditions for 24 hr. Then, the medium was changed to DMEM without polybrene and the cells were allowed to recover for 3 days. Cells were selected and maintained with puromycin (0.5 µg/ml for 293T, 1.5 µg/ml for HeLa) for several passages. Single cells were sorted into 96-well plates by a DiVa fluorescence-activated cell sorter (BD Biosciences) at the Duke Cancer Institute Flow Cytometry Shared Resource (DCI FCSR) to obtain individual clones. Clones were screened for successful vimentin deletion both by IP/IB with a monoclonal vimentin antibody (V9, Sigma) and quantitative RT-PCR (qPCR).

For qPCR, cellular mRNA was extracted with an RNeasy kit according to the manufacturer's instructions (Qiagen). RNA was used to generate cDNA using SuperScript II reverse transcriptase according to the manufacturer's instructions (Thermo Fisher \#18064014). cDNA was diluted five-fold, and triplicate reactions were performed using Sir Master Mix (Life Tech-Power Sybr no.4367659) according to manufacturer's instructions. Reactions were performed on a StepOnePlus Real-Time PCR system (Applied Biosystems).

The following qPCR primers and cycling conditions were used:

Vimentin {#s4-13}
--------

Forward: 5'-AGTGTGGCTGCCAAGAACCT 3'

Reverse: 5'-GAGGGACTGCACCTGTCTCC 3'

Actin {#s4-14}
-----

Forward: 5'-CACTCTTCCAGCCTTCCTTC 3'

Reverse: 5'-GGATGTCCACGTCACACTTC 3'

StepTemperature (°C)Time (minutes)CyclesInitial denaturation95101Denaturation\
Annealing\
Extension95\
60\
720.15\
0.3\
0.340Final extension72101Storage4∞-

Creation of vimentin-mEmerald lentivirus and reconstitution of vimentin^−/−^ cells {#s4-15}
----------------------------------------------------------------------------------

1.2 × 10^6^ 293 T cells were plated at \~60--70% confluency in a 6 cm dish 24 hr prior to transfection. Cells were transfected with:

-   1 µg vimentin expression construct (lentivector, produced as described above)

-   900 ng psPAX2 (packaging plasmid; Addgene plasmid \# 12260)

-   100 ng pMD2.G (VSV-G/ENV plasmid; Addgene plasmid \# 12259)

12--18 hr post-transfection, the medium was changed to 4 ml of DMEM with 30% FBS. At 48 hr post-transfection, the medium containing the virus was harvested and replaced with fresh DMEM. At 72 hr post-transfection, the virus-containing medium was again harvested, combined with the previous medium, and filtered through a 0.45 µm PVDF filter. Filtered supernatants were then used to infect target cells as described above. HeLa cells were selected and passaged in 500 µg/ml G418, and 293T cells with 100 µg/ml hygromycin. After trypsinizing, cells were resuspended in serum-free DMEM (+penicillin/streptomycin) and passed through a sterile 30 µm filter (Sysmex CellTrics, 04-004-2326). Cells were sorted on a DiVa fluorescence-activated cell sorter (BD Biosciences) at the DCI FCSR to obtain the top third of highest-expressing cells, as judged by GFP fluorescence (vimentin-mEmerald signal).

Filament imaging {#s4-16}
----------------

Imaging of vimentin-mEmerald was performed using a confocal laser scanning microscope (LSM 880; Zeiss) equipped with an automatic stage, Airyscan detector (Hamamatsu) and diode (405 nm), argon ion (488 nm), double solid-state (561 nm), and helium-neon (633 nm) lasers. Images were acquired using a 60x/1.4 NA oil objective (Zeiss) and deconvolved using automatic Airyscan Processing in the Zen Software (Zeiss).

Immunofluorescence {#s4-17}
------------------

Cells were rinsed twice with 37°C PBS and fixed with 1% formaldehyde (Sigma) in PBS for 10 min. Cells were permeabilized with PBS containing 0.1% Triton X-100 (Sigma) for 10 min and blocked with TBS containing 5% BSA (Equitech-Bio) and 0.1% Triton X-100. A mouse antibody against vimentin (clone V9, Santa Cruz Biotech sc-57678) was diluted in TBS containing 5% BSA and 0.1% Triton X-100 and incubated with the samples overnight at 4˚C. Cells were washed three times with PBS and then incubated with a goat anti-rabbit (H + L) Alexa Fluor 647-conjugated secondary antibody (Thermo Fisher) diluted in TBST containing 5% BSA for 1 hr at room temperature. Coverslips were washed five times with PBS and mounted on slides using ProLong Diamond anti-fade mounting medium with DAPI (Thermo Fisher). Cells were imaged using a confocal laser scanning microscope (LSM 880; Zeiss) equipped with an automatic stage, Airyscan detector (Hamamatsu) and diode (405 nm), argon ion (488 nm), double solid-state (561 nm), and helium-neon (633 nm) lasers. Images were acquired using a 60x/1.4 NA oil objective (Zeiss) and deconvolved using automatic Airyscan Processing in the Zen Software (Zeiss).

Transwell migration assays {#s4-18}
--------------------------

Transwell migration assays were performed essentially as described ([@bib60]). Briefly, cells were plated at approximately 70% confluency and allowed to attach for 24 hr. Then, the medium was removed and replaced with DMEM containing penicillin/streptomycin but lacking FBS for 72 hr. 6.5 mm Transwell plates with 8.0 µm pore polycarbonate membrane inserts were collagen-coated by incubating individual inserts in 50 µg/ml collagen solution from bovine skin (Sigma-Aldrich, C4243-20ML) for 1 hr at 37°C, UV-sterilized in a biosafety cabinet, and re-hydrated with FBS-free DMEM for 1 hr. FBS-starved cells were trypsinized and counted, and 30,000 cells per replicate were added to each insert with either FBS-containing or FBS-free DMEM on the opposite side. Cells were permitted to migrate for 24 hr under standard culture conditions. The assay was stopped by fixing cells in ice-cold methanol for 10 min at −20°C. Then, inserts were stained with crystal violet solution (30% methanol, 0.1% crystal violet in PBS) overnight. After staining, inserts were washed three times in PBS and the non-migrated cells were gently removed with a cotton swab. Four non-overlapping fields of view per insert were imaged with a 10x objective of a Nikon TE200 inverted microscope. Cells were counted manually using Fiji (NIH).

Statistical analysis {#s4-19}
--------------------

For filament morphology quantification, the number of puncta- and filament-containing cells was normalized as a percent of total cells counted and analyzed by ANOVA followed by pairwise t-tests, with p\<0.05 considered significant. Transwell migration assays were normalized to percent of control (i.e., WT vimentin, vehicle-treated, serum-stimulated) migration and analyzed by ANOVA followed by pairwise t-tests, with p\<0.05 considered significant.

*Chlamydia* strains and elementary body preparations {#s4-20}
----------------------------------------------------

*Chlamydia trachomatis* serotype LGV-L2, strain 434/Bu (CTL2) was propagated in Vero cells. Infectious elementary bodies (EBs) were derived from Vero-infected cells at 44 hr post-infection (hpi). Infected cells were rinsed twice with PBS, lysed in water for 10 min, and diluted in buffer (7.2 mM K~2~HPO~4~, 3.8 mM KH~2~PO~4~, 218 mM sucrose, 4.9 mM L-glutamic acid, pH 7.4). Cell lysates were subsequently sonicated and stored at −80°C.

*Chlamydia* infections {#s4-21}
----------------------

HeLa cells were seeded at a density of 5 × 10^4^ cells/well on glass coverslips (Bellco Glass, Inc.). Coverslips were pre-coated with 30 μg/ml type I collagen (Thermo Fisher) in 20 mM acetic acid (Spectrum) for 5 min and rinsed twice with medium. Cells were maintained in medium containing 0.5 mg/ml G418 and rinsed three times with medium lacking G418 just prior to infections. CTL2 EBs were added at a multiplicity of infection of three and infections were synchronized by centrifugation (1000 g, 20 min) at 10°C. The medium was replaced and infected cells were cultured under standard conditions for 30 hr. To inhibit OGT or OGA activity, the medium of infected cells was replaced with medium containing DMSO (vehicle), 50 µM 5SGlcNAc, or 50 µM Thiamet-G at 10 hpi.

Immunofluorescence in *Chlamydia* infection experiments {#s4-22}
-------------------------------------------------------

HeLa cells were rinsed twice with warm PBS and fixed with 3.7% formaldehyde in PBS for 20 min. Cells were quenched with 0.25% NH~4~Cl, permeabilized with PBS containing 0.1% Triton X-100 for 10 min, and blocked with PBS containing 2% BSA and 0.1% Triton X-100. A mouse antibody against MOMP (Santa Cruz, sc-57678) and a rabbit antibody against cap1 (A. Subtil, Institut Pasteur) were diluted in PBS containing 2% BSA and 0.1% Triton X-100. The secondary antibodies goat-anti-mouse (H + L) Alexa Fluor 647 (Thermo Fisher) and goat-anti-rabbit (H + L) Alexa Fluor 555 (Thermo Fisher) were diluted in PBS containing 2% BSA and 0.1% Triton X-100. Coverslips were washed five times with PBS and mounted on slides using Fluorsave mounting media (CalBiochem).

Cells were imaged using a confocal laser scanning microscope (LSM 880; Zeiss equipped with an automatic stage, Airyscan detector (Hamamatsu) and diode (405 nm), argon ion (488 nm), double solid-state (561 nm), and helium-neon (633 nm) lasers. Images were acquired using a 60x/1.4 NA oil objective (Zeiss) and deconvolved using automatic Airyscan Processing in the Zen Software (Zeiss).

Analysis of *Chlamydia* infection experiment images {#s4-23}
---------------------------------------------------

To quantify *Chlamydia* inclusion size, images were imported into ImageJ (NIH) and converted to 8-bit TIFF and binary image files to demarcate individual inclusions. The area of each cap1-positive inclusion and the number of extra-inclusion bacteria were exported and plotted in the R software. Datasets were analyzed in R using Levene's Test to assess equal variance, followed by either a Student's t-test or Welch's t-test, with p\<0.05 considered significant.

Vimentin cleavage {#s4-24}
-----------------

Vimentin^−/−^ HeLa cells stably transduced with empty vector or WT, S49A or Y117L vimentin-mEmerald were mock-infected or infected with CTL2 *Chlamydia* (MOI = 0.5) for 30 hr, washed twice with cold PBS, incubated in ice-cold buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1% Triton X-100, and protease inhibitors (Roche)) for 30 min and then sonicated on ice for 10 s. Cell lysates were cleared by centrifugation at 8000 rpm for five minutes at 4°C. Supernatants were diluted in SDS-PAGE sample buffer and heated to 95°C for five minutes. Equal volumes of sample were analyzed by IB. Rabbit antibodies against GFP (ThermoFisher A11122) and MOMP (a gift from Ken Fields), a mouse antibody against α-tubulin (Sigma-Aldrich, Clone B-5-1-2), and secondary anti-rabbit and anti-mouse antibodies (Li-Cor Biosciences) conjugated to infrared dye were diluted in PBS containing 5% nonfat milk (weight/volume) and 0.1% Tween-20, and sequentially incubated on the membrane prior to scanning with the Odyssey imaging system (Li-Cor Biosciences).

Transparent reporting {#s4-25}
---------------------

We have adhered to the definition of 'biological replicates' outlined by [@bib4] and paraphrased as independent, parallel measurements of biologically distinct samples to capture biological variation. By contrast, technical replicates are repeated measures of the same biological sample to determine the noise associated with experimental procedures or instruments ([@bib4]). Individual experiments shown in the figures are representative of at least three biological replicates. Statistical standards and tests for particular experiments are detailed in the appropriate subsections of the Materials and Methods and figure legends. For more information, please see the *eLife* Transparent Reporting form associated with this work.
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Decision letter
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Reviewing Editor
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Site-specific glycosylation regulates the form and function of the intermediate filament cytoskeleton\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Michael Marletta as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: John A Hanover (Reviewer \#1); Chad Slawson (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Although the reviewers are interested in your findings, there is some considerable concern with some aspects of the data (e.g. point 4).

Summary:

This is an interesting paper documenting an approach to understand the role of O-GlcNAcylation on IF structure and function. The authors demonstrate that O-GlcNAyclation of vimentin is important for normal function of the IF protein and that S49 on vimentin is the most critical O-GlcNAc site on the molecule. The studies with Chlamydia further extend the significance of the paper. The cross-linking approach uncovers interactions normally not accessible by other techniques.

Essential revisions:

1\) An important aspect of the conclusions made in this study related to the GlcNDAz crosslinking assay. I have several concerns that will need some testing in some cases and comments in others: i) Why is there significant variability is the relative stoichiometry of the crosslinked species vs. the vimentin monomer? ii) Related to point 1-i, do different anti-vimentin antibodies provide similar crosslinking profiles and can this potentially tell us something about the location of the crosslink (e.g., see the extent of myc vs. vimentin crosslinks in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}?. iii) The crosslinking efficiency likely depends on the conformation of the involved proteins. What is the crosslinking efficiency of vimentin in the presence or absence of 5SGlnNAc or Thiamet? iv) What happens to vimentin solubility in the context of different crosslinking conditions?

2\) Protein expression of the various constructs needs to be shown for at least some of the experiments where expression levels can alter the conclusion. This is particularly relevant for the cell migration effects shown in [Figure 4](#fig4){ref-type="fig"}. Expression of vimentin clearly enhances serum induced cell migration but the phenotype of the S49A and Y117L may be related to vimentin levels and any potential effect on the mutants on cell growth,

3\) If S49 glycosylation is important for baseline filament organization, one prediction is that its glycosylation stoichiometry would be expected to be high. It would be important to compare the glycosylation of vimentin WT vs. some of the other glycol-mutants shown in [Figure 3](#fig3){ref-type="fig"}. This can be done using in vitro galactosylation.

4\) Although the Plasmid Construction section of the Materials and methods indicates that the constructs were \'..miniprepped and sequenced...\" it would be important that the entire clones are sequenced in full (i.e., not only the inserts). May be this was done already but I am a bit surprised that all the mutants shown in [Figure 3](#fig3){ref-type="fig"} (except for the T33A mutant) had such a profound effect on vimentin organization.

5\) [Figure 5E](#fig5){ref-type="fig"}: the effect of 5SGlcNAc on inclusion area in HeLa cells that lack vimentin is not significant. What about the number of extra-inclusion bacteria?

6\) It is not surprising that the inclusion size is smaller for the two vimentin mutants (S49A and Y117L, [Figure 5](#fig5){ref-type="fig"}). Disruption of the vimentin cytoskeleton is predicted to interfere with any cellular process that involves vimentin reorganization. A previous report suggested the presence of a chlamydia-secreted protease that disrupts the keratin cytoskeleton (F Dong et al., Infect Immun 2004). It is possible that the vimentin mutations have altered susceptibility to degradation vs. WT vimentin. It would be important to tone down the importance of glycosylation in this process.

7\) How conserved is the S49-containing motif among other intermediate filament proteins. If conserved, are there known mutations in this residue in other intermediate filament proteins.

8\) Did the authors use OGA to cleave GlcNDAz in vitro (and see things go away) As a side note, GlcNDAz isn\'t turned over well in the cell and accumulates -- did they note any positive/negative consequences of that in their experiments? Why cycling? Not presence of?

9\) Results, ninth paragraph: do cells in which OGT/OGA are perturbed have same characteristics? This would suggest it\'s cycling (esp. if it\'s present w/ OGA perturbation) rather than the addition of OGlcNAc (and just OGT disruption).

10\) "Taken together, these results indicate that O-GlcNAcylation of vimentin, especially on S49, is required for optimal serum-stimulated cell migration." Is that the case? If so, does it get better with TMG treatment or siRNA orf OGA?

11\) Results, end of eleventh paragraph: is it possible that the 5SGlcNAc influences the chlamydia itself rather than just the host cell? What if it is treated with 5SGlcNAc (even if it\'s not known to have OGT, it might have an effect?)

12\) Results, end of last paragraph: did increased o-glcNAc improve response to chlamydia?

13\) [Figure 1](#fig1){ref-type="fig"}: were [Figures 1B and C](#fig1){ref-type="fig"} from the urea extraction method? This doesn\'t have to be chronological, but it seems important to note given that you only see it in that fraction...

14\) [Figure 2](#fig2){ref-type="fig"} would mutations of these expect to change the folding for any reason other than O-GlcNAcylation changes? There seems no independent analysis of vimentin abundance and stability.

15\) [Figure 3B](#fig3){ref-type="fig"}: what is being compared? WT to the other samples in the t-test or just the filaments/punctae within a sample? All samples? Statistics are unclear.

16\) [Figure 4](#fig4){ref-type="fig"}: here it is best to argue that residues subject to glycosylation are important for cell migration. Formally, it is difficult to tease out the role of O-GlcNAc at these sites since both the GlcNAc and the backbone is altered. It's also hard to tell what\'s being noted as statistically different here. I presume it\'s the difference between WT and the other three when serum stimulated? This should be better described either in the main text or in the legend. (i.e., vector is the -/- cell line without being reconstituted?).

17\) Were the cells +5SGlcNAc serum stimulated? Are these data the same as the samples on the left just with additional datapoints of the 5SGlcNAc? Consider just condensing to one graph or noting that. If the statistics become difficult and that\'s why it\'s split out, it should be easy to note in a table or graphically when \"NS\" is taken out. Also, for WT serum stimulated, are there error bars?

18\) [Figure 5A](#fig5){ref-type="fig"} legend: -/- is what is indicated I think?
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Author response

> Essential revisions:
>
> 1\) An important aspect of the conclusions made in this study related to the GlcNDAz crosslinking assay.

We agree with the reviewer that GlcNDAz crosslinking is a useful method for characterizing O-GlcNAc-mediated protein-protein interactions, but would also benefit from additional control experiments and clarifications in our manuscript.

> I have several concerns that will need some testing in some cases and comments in others: i) Why is there significant variability is the relative stoichiometry of the crosslinked species vs. the vimentin monomer?

Some variability in the extent of GlcNDAz-mediated vimentin crosslinking (i.e., crosslinked:uncrosslinked ratio) is likely due to cell type dependence. For example, the crosslinking in [Figure 1B](#fig1){ref-type="fig"} was performed in HeLa cells, whereas [Figures 1C-E](#fig1){ref-type="fig"} are from 293T cells. In addition, there is some intrinsic variability in the efficiency of each of the several steps in the GlcNDAz protocol, including the biosynthesis of UDP-GlcNDAz, the competition between UDP-GlcNDAz and abundant endogenous UDP-GlcNAc, the glycosylation of vimentin by OGT, the successful activation of the O-GlcNDAz diazirine by UV irradiation, and the productive insertion of the resulting carbene to form a covalent vimentin-vimentin crosslink (as opposed to the unproductive quenching of the carbene on a small molecule in the cytoplasm, for example)^1,2^. Since each of these steps is less than 100% efficient and subject to stochastic variability and/or cell type dependence, the final crosslinking results also vary somewhat. Importantly, however, these factors also mean that the crosslinking we observe almost certainly represents an underestimate of the extent of O-GlcNAc-mediated interactions among vimentin molecules, underlining their prevalence. In addition, the qualitative pattern of vimentin GlcNDAz crosslinking is highly reproducible across experiments and cell types (e.g., [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, Figure 1---figure supplements 1, 7), indicating that it reports on specific, conserved interactions. We have addressed these considerations in the fifth paragraph of the Results section.

> ii\) Related to point 1-i, do different anti-vimentin antibodies provide similar crosslinking profiles and can this potentially tell us something about the location of the crosslink (e.g., see the extent of myc vs. vimentin crosslinks in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}?

We have used two different commercial anti-vimentin monoclonal antibodies, D21H3 and V9, as well as the 9E10 anti-myc monoclonal antibody to detect GlcNDAz crosslinks of vimentin in several experiments (e.g., [Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplements 1B, C](#fig1s1){ref-type="fig"} and 7 with D21H3, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 2F](#fig1s2){ref-type="fig"} with V9, and [Figure 2](#fig2){ref-type="fig"} with 9E10). In the revised manuscript, we have stated which monoclonal was used in all applicable figure legends. We do not observe obvious differences in crosslinking when different antibodies are used (e.g., compare [Figure 1](#fig1){ref-type="fig"}, performed with D21H3, with [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 2F](#fig1s2){ref-type="fig"}, performed with V9). We agree with the reviewer that the site(s) of the vimentin crosslinks is of great interest, because knowing the site of carbene insertion into a second vimentin molecule might reveal a specific, O-GlcNAc-interacting motif. However, because, immunoblot (IB) analysis of GlcNDAz crosslinks is uniform across all antibodies used, this assay does not provide new information on that question. We have addressed these points to the fifth paragraph of the Discussion.

> iii\) The crosslinking efficiency likely depends on the conformation of the involved proteins. What is the crosslinking efficiency of vimentin in the presence or absence of 5SGlnNAc or Thiamet?

To address the reviewer's question, we have now performed GlcNDAz crosslinking in DMSO-, 5SGlcNAc- and Thiamet-G-treated cells ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). As expected, 5SGlcNAc treatment reduces GlcNDAz crosslinking of vimentin. In contrast, Thiamet-G treatment has little effect on crosslinking, likely because basal levels of vimentin glycosylation are high under physiological OGT expression conditions. In addition, we agree with the reviewer that the conformation of vimentin likely affects the efficiency and molecular topology of GlcNDAz crosslinks. All glycosylation sites that we characterized lie within the vimentin head domain, which is thought to be unstructured^3-8^. Because we observe reproducible, discrete crosslink products (cf. [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, Figure 1---figure supplements 1, 7), our results raise the possibility that the head domain may adopt a specific conformation through O-GlcNAc-mediated interactions in intermediate filaments (IF) in vivo. We have addressed these considerations in the Discussion section of the revised manuscript (fifth paragraph).

> iv\) What happens to vimentin solubility in the context of different crosslinking conditions?

As the reviewer notes, we extracted crosslinked vimentin samples into different buffers depending on the experimental need. For example, standard IBs were usually performed on crosslinked samples prepared in denaturing urea buffer (e.g., [Figures 1B and 1C](#fig1){ref-type="fig"}), whereas experiments involving immunoprecipitations (IPs) were performed with samples made in a standard, non-denaturing IP buffer (e.g., [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). As the reviewer anticipates, it is important to confirm that vimentin crosslinks are soluble in both buffers, because vimentin crosslinking could not be reliably detected and compared if GlcNDAz crosslinking itself renders vimentin insoluble in those buffers. To address this point, we have now performed a control experiment wherein we performed the differential extraction assay^9^ and then exchanged the crosslinks from the denaturing urea buffer into non-denaturing buffer ([Figure 1---figure supplement 2F](#fig1s2){ref-type="fig"}. This result demonstrates that the vimentin crosslinks are equally soluble in both cases, confirming the validity of comparing crosslink IBs performed with different buffers across experiments.

> 2\) Protein expression of the various constructs needs to be shown for at least some of the experiments where expression levels can alter the conclusion. This is particularly relevant for the cell migration effects shown in [Figure 4](#fig4){ref-type="fig"}. Expression of vimentin clearly enhances serum induced cell migration but the phenotype of the S49A and Y117L may be related to vimentin levels and any potential effect on the mutants on cell growth.

We agree with the reviewer that uniform expression of different wild type and mutant vimentin constructs in our reconstituted cells is critical. To confirm even expression, we used fluorescence-activated cell sorting to normalize the vimentin-mEmerald expression in all reconstituted HeLa and 293T cell lines. In the revised manuscript, we have updated the Materials and methods text to explain this fact, and have included a new figure from the flow cytometry data, demonstrating even expression of the various vimentin-mEmerald expression across these cell lines ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). These flow cytometry data are consistent with the microscopy ([Figures 3A](#fig3){ref-type="fig"} and Figure 3---figure supplement 4A) and quantitative IB ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}) data, which confirm uniform vimentin-mEmerald expression across cell lines at a level comparable to that of endogenous vimentin. Based on these controls, we believe the phenotypes we observe in our IF morphology, cell migration and *Chlamydia* infection assays are due to differences in vimentin genotype, and not differences in vimentin expression levels. We have revised the seventh paragraph of the Results section to clarify these points.

> 3\) If S49 glycosylation is important for baseline filament organization, one prediction is that its glycosylation stoichiometry would be expected to be high. It would be important to compare the glycosylation of vimentin WT vs. some of the other glycol-mutants shown in [Figure 3](#fig3){ref-type="fig"}. This can be done using in vitro galactosylation.

We agree with the reviewer that the stoichiometry of vimentin S49 glycosylation is an interesting and important question. We attempted a galactosyltransferase assay, as the reviewer suggested, but observed poor labeling in all samples, including cell lysates and commercial positive control proteins (α-crystallin) (not shown). As an alternative approach, we performed metabolic labeling with *N*-azidoacetylgalactosamine (GalNAz) to quantify O-GlcNAcylation^10-12^. We have previously demonstrated that GalNAz labeling and subsequent bioorthogonal chemical ligation permit the detection of authentic O-GlcNAcylation in live human cells^10-12^. We GalNAz-labeled cells transfected with vector only or wild type or S49A vimentin constructs, ligated an alkyne-Cy5 probe to O-GlcNAz moieties, IP-ed vimentin and analyzed Cy5 signal to quantify the extent of glycosylation ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). In this experiment, the Cy5 signal of the S49A mutant was approximately 80% of the wild type, suggesting that S49 glycosylation accounts for about one-fifth of total vimentin glycosylation under these conditions. We believe these results are consistent with our model that significant levels of S49 glycosylation promote IF formation or stability in live cells ([Figure 3](#fig3){ref-type="fig"}, Figure 3---figure supplement 4). These data are discussed in the sixth paragraph of the Results section.

> 4\) Although the Plasmid Construction section of the Materials and methods indicates that the constructs were \'..miniprepped and sequenced...\" it would be important that the entire clones are sequenced in full (i.e., not only the inserts). May be this was done already but I am a bit surprised that all the mutants shown in [Figure 3](#fig3){ref-type="fig"} (except for the T33A mutant) had such a profound effect on vimentin organization.

We agree with the reviewer that the IF morphology and functional phenotypes we observe in vimentin mutants are striking, supporting the importance of vimentin glycosylation in vivo. In prior e-mail correspondence with Dr. Marletta and the *eLife* staff, we addressed the question of sequencing our vimentin constructs raised in this comment. Briefly, we sequence-verified the entire open reading frames of all vimentin constructs used in our work to confirm their integrity and to rule out the possibility of any adventitious mutations. Importantly, site-directed mutagenesis was performed in a donor vector, and then wild type or mutant vimentin open reading frames were transferred to a destination vector via standard topoisomerase-based cloning methods. This workflow eliminates the possibility that the mutagenesis procedure introduced undetected mutations in the backbone vector, since the destination vectors were never subjected to site-directed mutagenesis. We have revised the "Plasmid Construction" subsection of the Materials and methods to explain this point.

> 5\) [Figure 5E](#fig5){ref-type="fig"}: the effect of 5SGlcNAc on inclusion area in HeLa cells that lack vimentin is not significant. What about the number of extra-inclusion bacteria?

We agree with the reviewer that it would be useful to determine the effects of 5SGlcNAc treatment on extra-inclusion *Chlamydia* in infected vimentin^-/-^ HeLa cells. We performed this experiment and now show that OGT inhibition has no effect on the number of extra-inclusion bacteria in cells lacking vimentin ([Figure 5E](#fig5){ref-type="fig"}, bottom panel, and Results, last paragraph). This result is consistent with our model that vimentin glycosylation sites and OGT activity are both required for IF remodeling by *Chlamydia*.

> 6\) It is not surprising that the inclusion size is smaller for the two vimentin mutants (S49A and Y117L, [Figure 5](#fig5){ref-type="fig"}). Disruption of the vimentin cytoskeleton is predicted to interfere with any cellular process that involves vimentin reorganization. A previous report suggested the presence of a chlamydia-secreted protease that disrupts the keratin cytoskeleton (F Dong et al., Infect Immun 2004). It is possible that the vimentin mutations have altered susceptibility to degradation vs. WT vimentin. It would be important to tone down the importance of glycosylation in this process.

As the reviewer notes, the *Chlamydia*-encoded CPAF protease cleaves host IF proteins^13^. Indeed, we have previously shown that vimentin in particular is a CPAF substrate during infection^14-17^. We agree with the reviewer that the effects of vimentin glycosylation on vimentin cleavage during infection are an important question. We now provide IBs demonstrating that the infection-dependent cleavage of vimentin is unaffected in the S49A and Y117L mutants (Figure 5---figure supplement 9). The observations that the S49A mutation does not affect vimentin cleavage by CPAF (Figure 5---figure supplement 9) but still prevents IF remodeling ([Figure 5C, D](#fig5){ref-type="fig"}) support the importance of vimentin glycosylation sites and OGT activity during *Chlamydia* infection. We also agree with the reviewer that any generic disruption in the vimentin cytoskeleton could interfere with IF reorganization during infection. In this regard, as the reviewer notes, the phenotypes we observe in the Y117L mutant are not surprising, since Y117L cannot assemble beyond the unit-length filament stage^18-21^. This property makes the Y117L mutant an appropriate positive control for vimentin IF disruption. Our data also demonstrate that, although S49A vimentin is capable of forming filaments (albeit at reduced levels) ([Figure 3](#fig3){ref-type="fig"} and Figure 3---figure supplement 4), S49 is required for the characteristic *Chlamydia*-induced vimentin IF remodeling during infection ([Figures 5](#fig5){ref-type="fig"}). We believe these results indicate a specific regulatory role for the S49 glycosylation site in *Chlamydia*-induced IF remodeling. Indeed, two other lines of evidence indicate that the phenotypes we observe with the S49A mutant are due to the loss of S49 glycosylation, and not to generic loss of IF assembly. First, 5SGlcNAc treatment reduces *Chlamydia* inclusion size and extra-inclusion bacteria in cells expressing wild type vimentin, but not cells lacking vimentin ([Figures 5A, B, E](#fig5){ref-type="fig"}), strongly arguing for a requirement for *both* OGT activity *and* vimentin in inclusion architecture. Second, prior studies have demonstrated that S49 is not required for IF formation, because vimentin mutants with internal head domain deletions spanning S49 are competent to form IFs in vitro and in vivo^22^. We believe these data, taken together, indicate that the IF phenotypes we observe in control and *Chlamydia*-infected cells are due to a loss of vimentin assembly regulation by O-GlcNAcylation at S49, and not due to an intrinsic, essential function of S49 per se. We have revised the manuscript in the eleventh and twelfth paragraphs of the Results section and in the second paragraph of the Discussion, to better explain these results and analyses.

> 7\) How conserved is the S49-containing motif among other intermediate filament proteins. If conserved, are there known mutations in this residue in other intermediate filament proteins.

As the reviewer anticipates, S49 is conserved among vimentin orthologs in other vertebrates, despite the lower overall conservation of the head domain compared to the rod domain (Figure 6---figure supplement 10A)^3-8^. Among the other human type III IF family members, S49 is conserved in desmin but not peripherin or glial fibrillary acidic protein (Figure 6---figure supplement 10B). These observations suggest that control of vimentin and perhaps desmin by O-GlcNAcylation at S49 or its cognate residue (desmin S51) could be evolutionarily conserved, an important hypothesis to test in future studies. It will also be interesting to determine whether O-GlcNAcylation exerts similar effects on other IFs, since numerous IF proteins are also glycosylated in vivo^23-35^. We are not aware of characterized mutations in S51 of desmin in human disease. However, mutations in the nearby S46 residue of desmin cause myofibrillar myopathy^36,37^ and could conceivably impact on desmin glycosylation at S51 (or even S46 itself), though this idea is speculative. We have added a brief discussion of these points in the last paragraph of the Results section.

*8) Did the authors use OGA to cleave GlcNDAz* in vitro *(and see things go away) As a side note, GlcNDAz isn\'t turned over well in the cell and accumulates -- did they note any positive/negative consequences of that in their experiments? Why cycling? Not presence of?*

An in vitro cleavage assay with recombinant-purified human OGA and GlcNDAz crosslinks is unlikely to succeed, since the covalent adducts formed by carbene insertion would almost certainly sterically occlude the crosslinked proteins from the OGA active site^38-41^. As an alternative experiment to address the reviewer's question, we demonstrated that overexpression of human OGA in GlcNDAz-labeled cells reduces subsequent vimentin crosslink formation, whereas OGT overexpression increases it ([Figure 1C](#fig1){ref-type="fig"}). As the reviewer notes, the Kohler lab has shown previously that the O-GlcNDAz moiety is turned over in cells more slowly than is the natural O-GlcNAc moiety^42^. Despite this important point, we believe our results confirm the specificity of GlcNDAz crosslinking and indicate that O-GlcNDAz cycles on vimentin, since its addition and removal can be potentiated by OGT or OGA overexpression, respectively ([Figure 1C](#fig1){ref-type="fig"}). For these reasons, we previously referred to O-GlcNAc "cycling," as opposed to "presence," in several places in the original text. We have revised the manuscript language to remove "cycling" and to be appropriately conservative in our description of the results. Finally, we note that we have used GlcNDAz as a discovery tool for examining the biochemical effects of glycosylation on vimentin, but have not deployed GlcNDAz in any cellular functional assays (e.g., migration or *Chlamydia* infection), which might be particularly sensitive to glycan turnover kinetics. Importantly, we have not observed any obvious deleterious effects of GlcNDAz labeling (e.g., apoptosis) with the doses and incubation times used in our experiments.

> 9\) Results, ninth paragraph: do cells in which OGT/OGA are perturbed have same characteristics? This would suggest it\'s cycling (esp. if it\'s present w/ OGA perturbation) rather than the addition of OGlcNAc (and just OGT disruption).

Our data demonstrate that GlcNDAz crosslinking in live cells is potentiated or reduced by overexpression of OGT or OGA, respectively ([Figure 1C](#fig1){ref-type="fig"}). As the reviewer suggests, we believe these data suggest that O-GlcNAc is cycling on vimentin, and not merely static, since manipulating OGT or OGA levels can affect the extent of O-GlcNDAz modification and subsequent crosslinking. We have revised the manuscript to provide a more conservative description of these results. We did not observe any obvious deleterious or differential phenotypic effects of OGT and OGA overexpression with the expression levels and incubation times used in our experiments.

> 10\) "Taken together, these results indicate that O-GlcNAcylation of vimentin, especially on S49, is required for optimal serum-stimulated cell migration." Is that the case? If so, does it get better with TMG treatment or siRNA orf OGA?

To address the reviewer's question, we now provide migration data with Thiamet-G-treated cells alongside vehicle- and 5SGlcNAc-treated cells ([Figure 4](#fig4){ref-type="fig"}). In cells expressing wild type vimentin, Thiamet-G treatment significantly reduced serum-induced migration, compared to vehicle alone (*p* = 0.006), albeit less dramatically than 5SGlcNAc did. In contrast, Thiamet-G treatment had no effect on serum-induced migration in cells expressing S49A (or Y117L) mutant vimentin. These results support our model that O-GlcNAcylation of vimentin at S49 is required for optimal serum-stimulated cell migration. We have revised the Results section (tenth paragraph) and [Figure 4](#fig4){ref-type="fig"} legend to discuss these new data.

> 11\) Results, end of eleventh paragraph: is it possible that the 5SGlcNAc influences the chlamydia itself rather than just the host cell? What if it is treated with 5SGlcNAc (even if it\'s not known to have OGT, it might have an effect?)

Because it is an obligate intracellular pathogen, free-living *Chlamydia* are unfortunately not culturable and therefore cannot be treated with 5SGlcNAc in isolation^43^. However, we believe it is very unlikely that 5SGlcNAc exerts its effects in our *Chlamydia* infection experiments through any pathogen-encoded target, because 5SGlcNAc has no impact on inclusion size or the number of extra-inclusion bacteria in vimentin^-/-^ host cells ([Figure 5E](#fig5){ref-type="fig"}). We have revised the last paragraph of the Results section to better highlight this point.

> 12\) Results, end of last paragraph: did increased o-glcNAc improve response to chlamydia?

To address the reviewer's question, we now provide *Chlamydia* infection data in Thiamet-G-treated cells expressing wild type, S49A or Y117L vimentin (Figure 5---figure supplement 6). Thiamet-G had no effect on inclusion area in any of these cell types, likely because basal levels of vimentin glycosylation are relatively high ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Indeed, this result is consistent with our observation that 5SGlcNAc lowers GlcNDAz crosslinking of vimentin, but Thiamet-G does not raise it ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We believe these data support our hypothesis that vimentin glycosylation is constitutively high, and that vimentin glycosylation sites and OGT activity are required for *Chlamydia*-induced IF remodeling. We discuss these new data in the tenth and eleventh paragraphs of the Results section.

> 13\) [Figure 1](#fig1){ref-type="fig"}: were [Figures 1B and C](#fig1){ref-type="fig"} from the urea extraction method? This doesn\'t have to be chronological, but it seems important to note given that you only see it in that fraction.

We apologize that these experimental details were not provided in our initial submission. The samples analyzed in [Figures 1B and C](#fig1){ref-type="fig"} were prepared in a denaturing urea buffer. We have revised the legend to [Figure 1](#fig1){ref-type="fig"} to supply this information.

> 14\) [Figure 2](#fig2){ref-type="fig"} would mutations of these expect to change the folding for any reason other than O-GlcNAcylation changes? There seems no independent analysis of vimentin abundance and stability.

We agree with the reviewer that the impact of O-GlcNAcylation site mutations on vimentin abundance and stability is an important question. In the revised manuscript, we provide flow cytometry data to demonstrate that vimentin-mEmerald expression is even across all reconstituted cell lines (wild type and mutants) ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). These results confirm the microscopy data from our original submission, which also reflect even expression of the wild type and mutant vimentin-mEmerald constructs across all reconstituted cell lines ([Figure 3](#fig3){ref-type="fig"} and Figure 3---figure supplement 4). To further rule out any effect of the S49A mutation on vimentin stability, we treated cells expressing wild type or S49A vimentin with vehicle only or the proteasome inhibitor MG132 and analyzed cell lysates by IB (Figure 3---figure supplement 5). These results revealed no discernible difference between wild type and S49A vimentin in the presence or absence of proteasome inhibition. Taken together, these data indicate that the phenotypes we observe in the S49A mutant are not due to differences in vimentin expression level or stability. We have revised the eighth paragraph of the Results section to address this point.

> 15\) [Figure 3B](#fig3){ref-type="fig"}: what is being compared? WT to the other samples in the t-test or just the filaments/punctae within a sample? All samples? Statistics are unclear.

We apologize that our statistical analysis of the filament/puncta quantitation ([Figure 3B](#fig3){ref-type="fig"}) was not clearly explained in the initial submission. We performed ANOVA analysis followed by pairwise t-tests to compare the filament data from each vimentin mutant to wild type, and to compare the puncta data from each vimentin mutant to wild type. All three vimentin mutants (S49A, Y117L, S49E) exhibited levels of puncta and filaments that were significantly different from those of wild type. These results support our model that S49 glycosylation regulates IF morphology. In addition, we performed t-tests comparing the puncta and filament levels of the S49A mutant and the phosphomimetic S49E mutant to each other. In this case, no significant difference was observed between the two mutants. This result (along with the lack of any literature reports of S49 phosphorylation) supports our conclusion that loss of glycosylation, and not loss of phosphorylation, likely explains the phenotypes of the S49A mutant in our assays. We have revised [Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, the Results section (eighth, ninth and tenth paragraphs) and the "Statistical analysis" subsection of the Materials and methods to clarify these points.

> 16\) [Figure 4](#fig4){ref-type="fig"}: here it is best to argue that residues subject to glycosylation are important for cell migration. Formally, it is difficult to tease out the role of O-GlcNAc at these sites since both the GlcNAc and the backbone is altered. It's also hard to tell what\'s being noted as statistically different here. I presume it\'s the difference between WT and the other three when serum stimulated? This should be better described either in the main text or in the legend. (i.e., vector is the -/- cell line without being reconstituted?).

We agree with the reviewer that it is challenging to stringently discriminate between the effects of lost glycosylation versus changes to the protein sequence per se in interpreting the phenotypes of individual glycosylation site mutants. As the reviewer suggests, we have revised both the Results and Discussion sections of the text to reflect the fact that our data demonstrate the importance of O-GlcNAcylation sites of vimentin for cell migration, a more parsimonious description of our results. Nevertheless, we believe two important lines of evidence suggest that it is likely loss of glycosylation, and not a change in amino acid sequence per se, that explains the phenotype of the S49A mutant in our cell migration assays ([Figure 4](#fig4){ref-type="fig"}). First, 5SGlcNAc and Thiamet-G treatment inhibit the serum-induced migration of cells expressing wild type vimentin but not cells lacking vimentin or cells expressing S49A vimentin ([Figure 4](#fig4){ref-type="fig"}). These results demonstrate that the S49 residue of vimentin is required for the inhibitory effect on cell migration of OGT or OGA inhibition. Second, prior studies have demonstrated that S49 is not required for vimentin IF assembly in vitro or in vivo, arguing against an O-GlcNAc-independent role for S49 in IF structure and function^22^. We believe the simplest interpretation of our data, taken together, is that loss of vimentin regulation by S49 glycosylation alters IF assembly state, accounting for the phenotype of the S49A mutant in the cell migration assay ([Figure 4](#fig4){ref-type="fig"}). With respect to the question of statistical comparisons, we apologize that this was not clear in the original text. For our cell migration data, we first performed an ANOVA, which compares all samples in a group at once to determine in which condition(s) the variance is significant. Then, given the significance indicated by the ANOVA, we performed pairwise t-tests for all combinations of data points. As the reviewer surmises, the serum-stimulated migration of wild type vimentin-expressing cells is significantly greater than the serum-stimulated migration of all three other cell types (vector, S49A and Y117L) ([Figure 4](#fig4){ref-type="fig"}). In addition, as noted above, 5SGlcNAc or Thiamet-G treatment significantly inhibits the serum-stimulated migration of cells expressing wild type vimentin, but not that of cells expressing any of the three mutants ([Figure 4](#fig4){ref-type="fig"}). We have revised the image and legend of [Figure 4](#fig4){ref-type="fig"} to clarify the most important comparisons made in our statistical analyses, without unduly cluttering the graph. In addition, we have revised the Materials and methods section to explain the statistical analysis in more detail, and have now provided source data with comprehensive statistical analyses, including all pairwise t-test results, in table format ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). To answer the final part of the reviewer's question, "vector" refers to vimentin^-/-^ cells stably transduced with an empty version of the backbone vector used to create the wild type and mutant vimentin-mEmerald constructs. We apologize that this was unclear in our initial submission, and we have revised the legend to [Figure 4](#fig4){ref-type="fig"} to rectify this.

> 17\) Were the cells +5SGlcNAc serum stimulated? Are these data the same as the samples on the left just with additional datapoints of the 5SGlcNAc? Consider just condensing to one graph or noting that. If the statistics become difficult and that\'s why it\'s split out, it should be easy to note in a table or graphically when \"NS\" is taken out. Also, for WT serum stimulated, are there error bars?

We apologize that these details of the cell migration assay were unclear. As the reviewer anticipates, the "+5SGlcNAc" data series in [Figure 4](#fig4){ref-type="fig"} represents cells stimulated with serum and treated with 5SGlcNAc. This also applies to the cells treated with Thiamet-G, which are new data provided in the resubmitted manuscript. We have revised the figure legend to clarify this point. Also, we have adopted the reviewer's suggestion to simplify [Figure 4](#fig4){ref-type="fig"} by consolidating the migration data into a single graph and by highlighting only the most important statistical comparisons. In addition, we have provided complete statistical analyses in table format as source data ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Finally, there are no error bars for the wild type serum-stimulated condition, because this experimental treatment was defined as maximum migration, fixed at 100% and used to normalize all other data. We have revised the legend to [Figure 4](#fig4){ref-type="fig"} to explain this analysis more carefully.

> 18\) [Figure 5A](#fig5){ref-type="fig"} legend: -/- is what is indicated I think?

We thank the reviewer for noticing this typo, which we have corrected in the revised manuscript. Indeed, the line should have begun "Vimentin^-/-^ HeLa cells reconstituted with WT vimentin-mEmerald..."
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